Diagnosing pharmaceutical regulatory agencies: A metacybernetic framework for innovation and governance

This study explores how pharmaceutical regulatory agencies can be understood and enhanced by applying a metacybernetic framework. It addresses the key research question: How can regulatory agencies in the pharmaceutical sector function as adaptive systems capable of timely sensing and evaluating emerging technologies, while preserving systemic safeguards for public health and safety? Drawing on Mindset Agency Theory (MAT), it applies a triadic subagency model to diagnose regulators' internal dynamics. Regulators are interpreted as evolving living systems that are capable of reflexive learning, stakeholder engagement, and ethical orientation. The model is grounded in systems theory and social cybernetics and is supported by examples from regulatory practices. This first application of the metacybernetic subagency framework to pharmaceutical regulation, offers a novel perspective for reform in the face of rising technological complexity, public scrutiny, and global health challenges. The triadic framework shows that agencies enhance adaptability by cultivating affective responsiveness (engagement), cognitive capability (data assimilation and learning), and spiritual integrity (ethical commitment). Current models often underutilise these capacities, resulting in rigid, siloed decision-making. This study extends metacybernetics into public governance, opening new avenues for analysing institutional reflexivity, resilience, and regulatory ethics. The findings suggest practical reforms, including ethical reviews, patient engagement, adaptive approvals, and AI-augmented decision support.